Swiss pharmaceutical company Sandoz is launching a generic semaglutide, the main ingredient of Ozempic, in the U.S. when the market opens in 2030, Bloomberg reported Sept. 3.
The company first plans to launch the generic, which is approved for Type 2 diabetes (Ozempic) and weight loss (Wegovy), in Canada when the patent for semaglutide expires in 2026.
Sandoz spun off from Novartis in October 2023 and focuses on manufacturing generic pharmaceuticals. The company is working on the generic Ozempic drug with the pharmaceutical company Pharmathen.
Read the latest GLP-1 drug updates from Becker's here.